Statins In Dialysis-Dependent End-Stage Renal Disease: Reconciling Discordant Evidence Through GRADE-Informed Appraisal and Evidence-to-Decision Framework
- Journal
- Journal of cardiovascular pharmacology (Q2)
- Published
- 28 August 2026
- Study design
- Randomized controlled trial
- Evidence level
- Level 1, High (CEBM 1b)
- Authors
- Mahmoud Abdelnabi, Ramzi Ibrahim, Aya Elalfy, Reza Arsanjani
- PMID
- 42664087
- DOI
- 10.1097/FJC.0000000000001876
Why clinicians should know about it
- Picked for Nephrology (top studies of the week, 30 August 2026).
Abstract
In dialysis-dependent end-stage renal disease patients (ESRD), statin use remains an evidence-use dilemma: randomized controlled trials (RCTs) suggested limited benefit from statin initiation, whereas observational cohort studies reported lower mortality and cardiovascular events. This discordance creates uncertainty in prescribing, resource allocation, guideline interpretation, and shared decision-making. This analysis assessed whether this apparent conflict reflects true inconsistency, risk of bias, indirectness, or limitations in translating evidence into recommendations. Using narrative synthesis, GRADE-informed appraisal, and evidence-to-decision principles, an evidence-based, patient-centered approach is proposed based on the current available evidence.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.